C]Martinostat positron emission tomography (PET).
Introduction
Epigenetic mechanisms have been associated with cognitive function through postmortem human and preclinical studies (1-3), but no direct associations have been made in the living human brain. This is because until recently (4), epigenetic neuroimaging tools did not exist. The epigenetic enzymes that control gene transcription could cause or respond to cell pathology, potentially leading to cognitive deficits in human diseases as diverse as schizophrenia (SCZ) and Alzheimer's disease. Using neuroimaging tools designed to measure the distribution of epigenetic enzymes, we can now begin to explore the relationships among the amount and location of enzymes, brain anatomy and function, and disease phenotypes. Of the epigenetic enzymes that can regulate gene transcription and influence behavior, histone deacetylases (HDACs) have emerged as potential targets for therapeutic interventions (5) (6) (7) (8) . In the healthy brain normal HDAC activity is critical for maintenance of neural cell identity, survival, and the activity-dependent regulation of neuroplasticity (2, (9) (10) (11) . Using [ (12) (13) (14) , an HDAC radiotracer, and positron emission tomography (PET), we previously mapped HDAC expression in healthy individuals (4) . Here we measure relative in vivo HDAC expression in the brain of patients with SCZ compared with healthy controls.
Preclinical studies link HDACs to cognitive circuitry. Abnormal amounts of HDACs disrupt cognition in rodents, evidenced through both molecular and behavioral phenotypes. For example, overexpression of HDAC2 in the mouse hippocampus BACKGROUND. Patients with schizophrenia (SCZ) experience chronic cognitive deficits. Histone deacetylases (HDACs) are enzymes that regulate cognitive circuitry; however, the role of HDACs in cognitive disorders, including SCZ, remains unknown in humans. We previously determined that HDAC2 mRNA levels were lower in dorsolateral prefrontal cortex (DLPFC) tissue from donors with SCZ compared with controls. Here we investigated the relationship between in vivo HDAC expression and cognitive impairment in patients with SCZ and matched healthy controls using [
Results

Study participants.
Written informed consent was received from participants prior to inclusion in the study (n = 22 subjects per group were enrolled). Eligible subjects with SCZ or SAD (n = 14, ages 22-65 years) were group matched to eligible healthy control subjects (n = 17, ages 23-65 years) on the basis of age, sex, smoking status (47) , and parental socioeconomic status ( Figure 1 and Table 1 ). Subjects with SCZ/SAD represented a chronic, medicated cohort with moderate symptom severity as determined by the Positive and Negative Syndrome Scale (PANSS) interview (48) ( (4, (12) (13) (14) . [ 11 C]Martinostat PET was performed to assess relative in vivo HDAC expression, with standard uptake value (SUV) normalized to whole brain mean (SUVR) used as the primary outcome measure. We previously determined that HDAC2 mRNA levels were significantly lower in postmortem DLPFC tissue from donors with SCZ compared with controls (37) . Therefore, we selected the DLPFC for a priori region-of-interest (ROI) analysis in the present imaging study (Figure 2A ). In accordance with our previous postmortem data (unpaired t test, P < 0.0001), [ 11 C]Martinostat SUVR in the DLPFC was significantly lower in subjects with SCZ/SAD compared with controls (unpaired t test, P = 0.0017) (Figure 2 , B and C). Correlations between SUVR in the DLPFC and cognitive performance scores were assessed. SUVR was positively associated with overall composite (Spearman's r = 0.36, P = 0.048), speed decreased synaptic protein density, impaired long-term potentiation, and negatively regulated memory formation, while Hdac2 deletion had opposing effects (15) . Analogously, Hdac2 deletion in postmitotic forebrain neurons enhanced working memory and extinction learning (16) . Furthermore, genetic mutation or knockdown of Hdac2 in the central nervous system improved spatial, associative, and threat recognition memory in mouse models of Pitt-Hopkins syndrome (Tcf4 +/-) (17) and Alzheimer's disease (CK-p25) (18, 19) . Encouragingly, small molecule HDAC inhibitors conferred cognitive benefits in rodent models of aging (20, 21) , neurodegeneration (6, (21) (22) (23) (24) (25) (26) , and neuropsychiatric (27) (28) (29) (30) (31) (32) (33) (34) disease. Taken together with observations of aberrant HDAC levels in postmortem human brain tissue from donors with Alzheimer's disease (18, 19, 35) , SCZ (29, (36) (37) (38) (39) (40) , depression (28, 37) , and bipolar disorder (39) , these findings suggest that HDAC-related mechanisms may play a fundamental role in human cognition.
The dorsolateral prefrontal cortex (DLPFC) is a brain region highly important in human cognition that contributes to executive functioning, including working memory, planning, and mental flexibility (41) (42) (43) (44) . Previously, we observed that HDAC2 mRNA levels were 32% lower in the DLPFC of donors with SCZ (n = 175) compared with controls (n = 210), with no difference in HDAC1 mRNA levels (37) . The HDAC2 deficit was unique to donors with SCZ among the psychiatric disorders tested, including bipolar disorder (n = 61) and major depressive disorder (n = 135) (37) . Based on these data we hypothesized that regional [ 11 C]Martinostat uptake would be lower in the DLPFC of patients with SCZ. However, other groups observed higher HDAC1 mRNA levels in the prefrontal cortex (n = 16-27 per group) (36, 38) , as well as in GABAergic hippocampal neurons (n = 7 per group) (39) from donors with SCZ compared with controls. As studies using postmortem tissue are limited by both physiological differences and spatial sampling constraints, this underscores the potential utility of [ Moreover, SCZ represents an example of a chronic cognitive disorder, as more than 75% of patients show a wide range of cognitive deficits, with mean effect sizes one standard deviation below population means (45) . Cognitive impairment manifests early during the course of SCZ and typically persists, in part because current antipsychotic regimens do not affect cognition (45, 46) . (Figure 2A , blue) and within frontal cortex regions as detected by voxel-wise analysis ( Figure 3A, blue) . No significant differences between subjects with SCZ/SAD and controls were found (unpaired t test, P > 0.05) (Supplemental Figure 2A) , demonstrating that cortical thinning did not drive [
11 C]Martinostat uptake alterations in these regions. SUVR in the DLPFC (Figure 2A , blue) and SUVR in regions detected by voxel-wise analysis ( Figure 3A , blue or red) did not correlate with chlorpromazine (CPZ) equivalent dose (52), a metric of antipsychotic drug exposure, in subjects with SCZ/SAD (Spearman's correlation analysis, P > 0.05) (Supplemental Figure 2B ). These data suggest that antipsychotic medication usage did not drive [
11 C]Martinostat uptake alterations in these regions. As antipsychotic drug exposure was shown to increase HDAC2 protein expression in the frontal cortex (29, 53, 54) of rodents, [ 11 C]Martinostat uptake differences may be more pronounced when comparing controls with medication-free subjects with SCZ/SAD.
Discussion
Dysfunction of the DLPFC has been consistently associated with executive function deficits in SCZ (42) (43) (44) . We previously discovered that HDAC2 mRNA levels were lower in postmortem DLP-FC tissue from donors with SCZ compared with control donors (37) . This result was the basis of our hypothesis that regional [
C]
Martinostat uptake would be lower in the DLPFC of patients with SCZ. Through a priori region-of-interest analysis, we found that SUVR in the DLPFC was indeed lower in subjects with SCZ/SAD compared with healthy controls. Using unbiased whole brain voxel-wise analysis, we identified additional regions of the frontal cortex that showed lower SUVR in subjects with SCZ/SAD compared with controls, including the dorsomedial prefrontal cortex and the orbitofrontal gyrus, which have been associated with SCZ pathology (55) . We further found that the cerebral white matter, fusiform gyrus, pons, and cerebellar regions important for cognitive processes (56-58) showed higher SUVR in subjects with SCZ/ SAD compared with controls. Subregions of the cerebral white matter and cerebellum cortex displayed the strongest statistical differences between groups, suggesting that HDACs may play a particularly important role in these brain regions. Together these results suggest an HDAC imbalance in the brain of patients with SCZ. However, as our study measures changes in [ 11 C]Martinostat uptake relative to the whole brain mean (SUVR), and not absolute of processing (Spearman's r = 0.38, P = 0.036), and social cognition (Spearman's r = 0.53, P = 0.0023) MATRICS domains across groups ( Figure 2D ). Other MATRICS domains and PANSS scores did not show significant relationships with SUVR in the DLPFC (Spearman's correlation analysis, P > 0.05).
Unbiased whole brain voxel-wise analysis of [ 11 C]Martinostat uptake in subjects with SCZ/SAD compared with controls. Exploratory voxel-wise analysis was performed to further localize the DLPFC effect, as well as to evaluate relative [
11 C]Martinostat uptake differences between groups across the whole brain (unpaired t test, Z > 2.3, P cluster < 0.05). SUVR was significantly lower in multiple regions of the frontal cortex, including the DLPFC (specifically the rostral middle frontal gyrus and a portion of the superior frontal gyrus), dorsomedial prefrontal cortex, and orbitofrontal gyrus of subjects with SCZ/SAD compared with controls ( Figure 3 and Table 3 ). SUVR was significantly higher in the cerebral white matter, fusiform gyrus, cerebellum, and pons of subjects with SCZ/SAD compared with controls ( Figure 3 and Table 3 ). At an even stricter statistical threshold (unpaired t test, n = 10,000 permutations, familywise error rate-corrected P [P FWE ] < 0.05), SUVR was significantly higher in the cerebral white matter and cerebellum of subjects with SCZ/SAD compared with controls (Supplemental Figure 1 , A and B; supplemental material available online with this article; https://doi.org/10.1172/JCI123743DS1). To investigate the potential impact of HDAC expression in these regions, preliminary correlations between SUVR in the cerebral white matter or cerebellum cortex (anatomical ROIs) and cognitive performance scores were assessed in subjects with SCZ/SAD. In the cerebral white matter, but not the cerebellum cortex, SUVR was negatively associated with overall composite (Spearman's r = -0.64, P = 0.015), speed of processing (Spearman's r = -0.86, P = 0.0002), attention vigilance (Spearman's r = -0.75, P = 0.0027), working memory (Spearman's r = -0.69, (4) . We assayed mRNA levels of genes known to be regulated by HDAC (18) and critical for synaptic plasticity (60, 61) such as early growth response 1 (EGR1), brain-derived neurotrophic factor (BDNF), and synaptophysin (SYP). Notably, EGR1 is also associated with SCZ risk (62) , and decreased EGR1 expression has been observed in DLPFC tissue from donors with SCZ (n = 35-62) (62, 63) . Martinostat treatment increased EGR1, BDNF, and SYP gene expression (4) . These data could indicate a relationship between HDAC amount and human cognitive circuitry, and may support the potential utility of HDAC inhibitors as therapeutics for SCZ. However, future studies using neurons derived from patients with SCZ and genetic modulation of HDAC expression are required to strengthen this hypothesis (64, Martinostat PET studies with arterial blood sampling are required to validate HDAC expression differences in these newly identified regions. Our consistent findings in the DLPFC by both imaging and postmortem analyses indicate that these key next steps are warranted.
Subjects with SCZ/SAD exhibited cognitive deficits, including in executive functions, and cognitive performance scores positively correlated with SUVR in the DLPFC across groups. Preliminary findings also showed that in subjects with SCZ/SAD, cognitive performance scores negatively correlated with SUVR in the cerebral white matter. These data may suggest that abnormal HDAC expression, in either direction, could have negative effects on cognition. Alternatively, preclinical evidence suggests that HDAC deficiency may be beneficial in cognitive disorders by restoring neuronal function and promoting synaptic plasticity. A multitude of studies found that HDAC inhibitor treatment enhanced cognitive performance in rodents (6, 15, (20) (21) (22) (23) (24) (25) (27) (28) (29) (30) (31) (32) . (4) .
MR-PET data acquisition and reconstruction. An intravenous catheter was placed in the antecubital vein of the arm, and ~5 mCi [ 11 C]Martinostat (5.08 ± 0.33 mCi for control subjects; n = 17) and (5.04 ± 0.28 mCi for subjects with SCZ/SAD; n = 14) was injected as a manual bolus over a period of less than 1 minute by a licensed nuclear medicine technologist. Participants were instructed to remain still for the entire duration of the 90-minute scan. MR and PET images were acquired on a 3T Siemens TIM Trio with a BrainPET insert using an 8-channel head coil (70) . An anatomical T1-weighted multi-echo MPRAGE sequence (MEMPRAGE) with echo-planar imaging (EPI) navigator that allows prospective motion correction (71, 72) [TI] , 1100 ms; flip angle, 7°; and isotropic resolution, 1 mm) was acquired. To account for motion between MEMPRAGE acquisition and the PET frame of interest, the MEMPRAGE was realigned to a single reference PET frame 60-90 minutes after radiotracer injection. MR-based attenuation correction was applied using a statistical parametric mapping (SPM), pseudo-computed tomography method (73) . PET data were binned into six 5-minute frames spanning 60-90 minutes after radiotracer injection and reconstructed using the three-dimensional ordinary Poisson ordered-subset expectation maximization (3D OP-OSEM) algorithm with detector efficiency, decay, dead time, attenuation, and scatter corrections applied (74, 75) . The final PET images were reconstructed into 153 slices with 256 × 256 pixels and a 1.25-mm isotropic voxel size in the units of SUV. The final MR images were reconstructed with FreeSurfer version 6.0 (http://surfer. nmr.mgh.harvard.edu/) (76). 65). In particular, using induced pluripotent stem cell-derived neuronal models from patients imaged with [ 11 C]Martinostat would allow for a unique and powerful interplay between in vivo observations and ex vivo mechanistic insights within the same genetic landscape (66) .
In conclusion, our study presents in vivo evidence of human neuroepigenetic dysregulation in SCZ and provides the foundation for using [ 
Methods
Study design. Our main research objective was to compare relative [ 11 C] Martinostat brain uptake between subjects with SCZ/SAD and groupmatched healthy controls using magnetic resonance-PET (MR-PET). SUV collected 60-90 minutes after radiotracer injection, normalized to whole brain mean (SUVR), was the primary endpoint assessed. Data from 2 subjects were excluded: a subject with SCZ exited the scanner before the 60-to 90-minute time point, and a control subject was found to use psychotropic medications. Imaging studies were not blinded, and no outliers were excluded.
Participants. All participants provided written informed consent. Participants underwent a physical examination with a licensed physician or nurse practitioner. Medical history, smoking status, and medication use were recorded. Illicit drug use was assessed by a urine drug screen (Discover Drug Test Card DIS-DOA-3124, American Screening Corp.). A serum pregnancy test (Sure-Vue serum hCG-STAT, Fisher HealthCare) was performed for female participants of childbearing potential to ensure no pregnancy at the time of the scan.
Inclusion/exclusion criteria for participants. Subjects with a diagnosis of SCZ or SAD were group matched for age, sex, smoking status, and parental socioeconomic status with healthy controls. One subject with SCZ/SAD was unable to provide parental socioeconomic information, and one subject with SCZ/SAD took nicotine replacement therapy and The number of subjects taking each medication is indicated in parentheses. CPZ equivalents and PANSS scores represent mean ± SD. jci.org Volume 129 Number 1 January 2019
Image analyses. In order to correct for inter-frame motion, the MCFLIRT tool (77) (78) (79) In brief, PET data corresponding to 5-minute bins spanning 60-90 minutes after radiotracer injection were smoothed 6 mm and aligned to a mean volume image using rigid body linear registration with 6 degrees of freedom. The motion correction matrix was applied to the unsmoothed PET data using FSL's applyxfm4d. PET data were averaged to create a motion-corrected, unsmoothed mean image for each subject, which was then registered to the subject's MEMPRAGE using mri_coreg from FreeSurfer 6.0 (76) and skull-stripped. The MEM-PRAGE was registered to Montreal Neurological Institute (MNI) space using linear (FLIRT [FMRIB's linear image registration tool]) (80, 81) and nonlinear (FNIRT [FMRIB's nonlinear image registration tool]) (82) algorithms in FSL, and the registration matrix was applied to move the PET image into MNI space. The PET image was intensity normalized to whole brain mean as SUVR (83, 84) to measure relative differences in [ 11 C]Martinostat uptake, while controlling for interindividual differences in global signal. The SUVR image was spatially smoothed 8 mm full width at half maximum. A priori ROI analysis of SUVR was performed between groups for the DLPFC. The DLPFC surface label was based on work by Yendiki et al. (85) and was converted into a volume in MNI space using FreeSurfer's mri_label2vol. Whole brain voxel-wise analysis of SUVR was performed between groups using FSL's FEAT with ordinary least squares (OLS) mixed-effects modeling, a significance threshold of Z > 2.3, and cluster correction of P cluster < 0.05 (86) . Whole brain voxel-wise analysis was also performed using FSL's randomise with 10,000 permutations, threshold-free cluster enhancement (TFCE), and P FWE < 0.05. Age and sex were added as nuisance regressors in voxel-wise analyses. Correlations between anatomical ROIs and cognitive performance scores were performed with SUVR images (spatially smoothed 8 mm full width at half maximum) in native space using masks for the cerebral white matter and cerebellum cortex generated by FreeSurfer's automated parcellation and segmentation (76). FreeSurfer's mri_segstats was used to measure cortical thickness. Anatomical regions were described using Atlas of the Human Brain (87) . Statistics. Demographic variables and MATRICS domains were compared between groups using unpaired 2-tailed t tests (Table 1) . For a priori ROI analysis of SUVR or postmortem HDAC2 mRNA comparisons between groups in the DLPFC, unpaired 2-tailed t tests were performed ( Figure 2 , B and C). Spearman's correlation analysis was performed to investigate the association between SUVR in the DLPFC and MATRICS or PANSS scores ( Figure 2D ). For whole brain voxel-wise SUVR comparisons between groups, an unpaired 2-tailed t test was performed with Z > 2.3 and P cluster < 0.05 correction ( Figure 3 and Table 3 ). For whole brain voxel-wise SUVR comparisons between groups, a nonparametric unpaired 2-tailed t test was also performed with TFCE and P FWE < 0.05 (Supplemental Figure 1, A and B ). Spearman's correlation analysis was performed to investigate the association between SUVR in the cerebral white matter, or SUVR in the cerebellum cortex, and MATRICS or PANSS scores (Supplemental Figure 1C) . Cortical thickness was compared between groups using unpaired 2-tailed t tests for the DLPFC and for the post hoc statistically significant area (decreased in SCZ/SAD) revealed by voxel-wise analysis (Supplemental Figure 2A ). Spearman's correlation analysis was used to investigate the association between SUVR in the DLPFC, or SUVR in the post hoc statistically significant areas (decreased or increased in SCZ/SAD) revealed by voxel-wise analysis, and CPZ equivalent dose exposure (Supplemental Figure 2B) . 
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